ÈËÆÞÖгöÊÓƵ

Sarang K. Yoon
( out of 15 reviews )

Sarang K. Yoon, DO, MOH

Languages spoken: English

Clinical Locations

Redwood ÈËÆÞÖгöÊÓƵ Center

Occupational Medicine
Salt Lake City

  • Dr. Yoon is an Associate Professor at the ÈËÆÞÖгöÊÓƵ of Utah School of Medicine, Division of Occupational and Environmental ÈËÆÞÖгöÊÓƵ, and Rocky Mountain Center for Occupational and Environmental ÈËÆÞÖгöÊÓƵ (RMCOEH). Her responsibilities include research, teaching, administration, and patient care. She is board-certified in Occupational Medicine. She has served as a site PI on a multicenter on COVID-19 vaccine effectiveness in a prospective cohort of frontline workers and ÈËÆÞÖгöÊÓƵren with Centers for Disease Control and Prevention (CDC). She also served as a site PI on a multicenter clinical trial on influenza vaccine efficacy with the CDC. At present, she is conducting an investigator-initiated clinical trial on COVID-19 boosters. In addition to research, she enjoys teaching and mentoring and looks forward to the opportunity further to develop this aspect of scholarship in her career. She practices at the Redwood Clinic in West Valley where she precepts resident physicians and medical students. She is the course director for OEHS 6504 Clinical and Behavioral Aspects of Preventive Medicine. She is the Associate Program Director for the Occupational Medicine Residency. In addition to her clinical and academic responsibilities, she serves as a medical director/occupational health specialist for companies and the federal government to promote worker safety and health.

    Specialties

    Board Certification

    American Board of Preventive Medicine (Occupational Medicine)

    Patient Rating

    4.4 /5
    ( out of 15 reviews )

    The patient rating score is an average of all responses on our patient experience survey. The rating averages scores for all questions about care from our providers.

    The scale on which responses are measured is 1 to 5 with 5 being the best score.

    Patient Comments

    Patient comments are gathered from our patient experience survey and displayed in their entirety.
    Patients are de-identified for confidentiality and patient privacy.

    July 19, 2024
    REDWOOD HEALTH CENTER

    Muy amable y atenta

    August 23, 2023
    REDWOOD HEALTH CENTER

    She really listened to me, and didn't just try to give me a quick answer, instead she tried to understand where I was coming from

    April 26, 2023
    REDWOOD HEALTH CENTER

    She was great and compassionate, and got me in quickly, as well as explaining many things to me.

    March 26, 2023
    REDWOOD HEALTH CENTER

    I didn't work with Dr. Yoon directly or talk with her directly, but the comments and results I got back on my chart were very helpful.

    March 24, 2023
    REDWOOD HEALTH CENTER

    Very nice

    February 08, 2023
    REDWOOD HEALTH CENTER

    Very friendly, fast service caring about people

    January 21, 2023
    REDWOOD HEALTH CENTER

    I really liked her personality. She was very concerned and caring.

    January 13, 2023
    REDWOOD HEALTH CENTER

    Es muy amable y me entiende en mi situacin y me aclara mis dudas

  • Dr. Yoon is an Associate Professor at the ÈËÆÞÖгöÊÓƵ of Utah School of Medicine, Division of Occupational and Environmental ÈËÆÞÖгöÊÓƵ, and Rocky Mountain Center for Occupational and Environmental ÈËÆÞÖгöÊÓƵ (RMCOEH). Her responsibilities include research, teaching, administration, and patient care. She is board-certified in Occupational Medicine. She has served as a site PI on a multicenter on COVID-19 vaccine effectiveness in a prospective cohort of frontline workers and ÈËÆÞÖгöÊÓƵren with Centers for Disease Control and Prevention (CDC). She also served as a site PI on a multicenter clinical trial on influenza vaccine efficacy with the CDC. At present, she is conducting an investigator-initiated clinical trial on COVID-19 boosters. In addition to research, she enjoys teaching and mentoring and looks forward to the opportunity further to develop this aspect of scholarship in her career. She practices at the Redwood Clinic in West Valley where she precepts resident physicians and medical students. She is the course director for OEHS 6504 Clinical and Behavioral Aspects of Preventive Medicine. She is the Associate Program Director for the Occupational Medicine Residency. In addition to her clinical and academic responsibilities, she serves as a medical director/occupational health specialist for companies and the federal government to promote worker safety and health.

    Board Certification and Academic Information

    Academic Departments Family & Preventive Medicine -Primary
    Board Certification
    American Board of Preventive Medicine (Occupational Medicine)

    Education history

    Chief Resident Occupational Medicine - ÈËÆÞÖгöÊÓƵ of Utah School of Medicine Chief Resident
    Occupational ÈËÆÞÖгöÊÓƵ - ÈËÆÞÖгöÊÓƵ of Utah School of Medicine M.O.H.
    Residency Occupational Medicine - ÈËÆÞÖгöÊÓƵ of Utah School of Medicine Resident
    Internal Medicine - West Anaheim Medical Center Intern
    Professional Medical Osteopathic Medicine - Touro ÈËÆÞÖгöÊÓƵ Nevada College of Osteopathic Medicine D.O.
    Pre-Medical and General Science Studies - ÈËÆÞÖгöÊÓƵ of California, Los Angeles Certificate
    Undergraduate Spanish - ÈËÆÞÖгöÊÓƵ of California, Los Angeles B.A.

    Selected Publications

    Journal Article

    1. Feldstein LR, Britton A, Grant LYoon SKet al (2024). Effectiveness of Bivalent mRNA COVID-19 Vaccines in Preventing SARS-CoV-2 Infection in Children and Adolescents Aged 5 to 17 Years. JAMA, 331(5), 408-416.
    2. Rivers P, Porter C, LeClair LBYoon SK, Lutrick K (2024). Longitudinal parental perception of COVID-19 vaccines for ÈËÆÞÖгöÊÓƵren in a multi-site, cohort study. Vaccine, Epub ahead of print.
    3. Hollister J, Caban-Martinez AJ, Ellingson KDYoon SKet al (2023). Serum per- and polyfluoroalkyl substance concentrations and longitudinal change in post-infection and post-vaccination SARS-CoV-2 antibodies. . Environ Res, Epub 2023 Oct 8.
    4. Lyski ZL, Porter C, Uhrlaub JLYoon SKet al (2023). Humoral Immune Response to mRNA COVID-19 Vaccination Among Children 5-11 in a Multisite Prospective Cohort study. Open Forum Infect Dis, 10(8), ofad431.
    5. Ellingson KD, Hollister J, Porter CYoon SKet al (Published). Risk Factors for Reinfection with SARS-CoV-2 Omicron Variant among Previously Infected Frontline Workers. Emerg Infect Dis, 29(3), 599-604.
    6. Herring MK, Romine JK, Wesley MGYoon SKet al (Published). Severe Acute Respiratory Syndrome Coronavirus 2 Infection History and Antibody Response to 3 Coronavirus Disease 2019 Messenger RNA Vaccine Doses. Clin Infect Dis, 76(10), 1822-1831.
    7. Thompson MG, Yoon SK, Naleway ALHEROES-RECOVER Network Investigators (Published). Association of mRNA COVID-19 Vaccination with Clinical and Virologic Features of COVID-19 among US Essential and Frontline Workers    . JAMA, 328(15), 1523-1533.
    8. Lutrick K, Rivers P, Fowlkes AL, Yoon SK (2022). Parental Intentions and Perceptions Toward COVID-19 Vaccination Among Children Aged 4 Months to 4 Years - PROTECT Cohort, Four States, July 2021-May 2022. MMWR Morb Mortal Wkly Rep, 71(35), 1109-1114.
    9. Veguilla V, Fowlkes AL, Bissonnette AYoon SKet al (2022). Detection and Stability of SARS-CoV-2 in Three Self Collected Specimen Types: flocked midturbinate swab (MTS) in viral transport media, foam MTS, and saliva. Microbiol Spectr, 10(3), e0103322.
    10. Yoon SK, Hegmann KT, Thiese MSHEROES-RECOVER Network Investigators (2022). Protection with a Third Dose of mRNA Vaccine against SARS-CoV-2 Variants in Frontline Workers    . New England Journal of Medicine (International Edition), 386(19), 1855-1857.
    11. Fowlkes AL, Yoon SK, Lutrick K, et al (2022). Effectiveness of 2-Dose BNT162b2 (Pfizer BioNTech) mRNA Vaccine in Preventing SARS-CoV-2 Infection Among Children Aged 5-11 Years and Adolescents Aged 12-15 Years - PROTECT Cohort, July 2021-February 2022. MMWR Morb Mortal Wkly Rep, 71(11), 422-428.
    12. Burns J, Rivers P, LeClair LB, Yoon SKet al (2022). Pediatric Research Observing Trends and Exposures in COVID-19 Timelines (PROTECT): Protocol for a Multisite Longitudinal Cohort Study. JMIR Res Protoc, 11(7), e37929.
    13. Lutrick K, Groom H, Fowlkes AL, Yoon SK (2022). COVID-19 Vaccine Perceptions and Uptake in a National Prospective Cohort of Essential Workers. Vaccine, 40(3), 494-502.
    14. Naleway AL, Grant L, Caban-Martinez AJYoon SKet al (2022). Incidence of SARS-CoV-2 infection among COVID-19 vaccinated and unvaccinated healthcare personnel, first responders, and other essential and frontline workers: Eight US locations, January-September 2021. Influenza Other Respir Viruses, 16(3), 585-593.
    15. Lutrick K, Rivers P, Yoo YM, Yoon SKet al (2021). Interim Estimate of Vaccine Effectiveness of BNT162b2 (Pfizer-BioNTech) Vaccine in Preventing SARS-CoV-2 Infection Among Adolescents Aged 12-17 Years - Arizona, July-December 2021. MMWR Morb Mortal Wkly Rep, 70(5152), 1761-1765.
    16. Tyner HL, Burgess JL, Grant MS, Yoon SKet al (2021). Neutralizing Antibody Response to Pseudotype SARS-CoV-2 Differs between mRNA-1273 and BNT162b2 COVID-19 Vaccines and by History of Natural Infection. Clin Infect Dis, 75(1), e827-e837.
    17. Edwards LJ, Fowlkes AL, Wesley MGYoon SKet al (2021). Research on the Epidemiology of SARS-CoV-2 in Essential Response Personnel (RECOVER): study design and methods for a multi-site longitudinal cohort  . JMIR Res Protoc, 10(12), e31574.
    18. Fowlkes A, Gaglani M, Groover K, HEROES-RECOVER Network (2021). Effectiveness of COVID-19 Vaccines in Preventing SARS-CoV-2 Infection Among Frontline Workers Before and During B.1.617.2 (Delta) Variant Predominance — Eight U.S. Locations, December 2020–August 2021. MMWR Morb Mortal Wkly Rep, 70(34), 1167-1169.
    19. Thompson MG, Burgess JL, Naleway AL, Tyner H, Yoon SK, et al (2021). Prevention and Attenuation of Covid-19 with the BNT162b2 and mRNA-1273 Vaccines. New England Journal of Medicine (International Edition), 385(4), 320-329. ()
    20. Thompson MG, Burgess JL, Naleway AL, Tyner HL, Yoon SK, et al (2021). Interim Estimates of Vaccine Effectiveness of BNT162b2 and mRNA-1273 COVID-19 Vaccines in Preventing SARS-CoV-2 Infection Among ÈËÆÞÖгöÊÓƵ Care Personnel, First Responders, and Other Essential and Frontline Workers — Eight U.S. Locations, December 2020–March 2021. MMWR Morb Mortal Wkly Rep, 70(13), 495–500.
    21. Yoon SK, Thiese MS, Ott U, Kapellusch J, Merryweather A, Wood EM, Ronna BB, Foster J, Drury DL, Hegmann KT (2019). The Role of Elbow Tender Point Examination in the Diagnosis of Lateral Epicondylitis.  . J Occup Environ Med, 61(2), 126-131.

    Book Chapter

    1. Mumenthaler S, Yoon NK, Li A, Mah V, Chang G, Nooraie F, Elshimali Y, Hanna S, Kim S, Horvath S, Apple S, Chia D, Seligson DB, Goodglick L (2008). Tissue Microarrays: Construction and Utilization For Biomarker Studies. In Hayat MA (Ed.), Methods of Cancer Diagnosis, Therapy, and Prognosis. Springer.

    Letter

    1. Thompson MG, Grant L, Meece J, HEROES-RECOVER Network (2021). Prevention of Covid-19 with the BNT162b2 and mRNA-1273 Vaccines. Reply. [Letter to the editor]. New England Journal of Medicine (International Edition), 385(19), 1819-1821.

  • News & Podcasts

    News

  • Clinical Trials